Less Ads, More Data, More Tools Register for FREE

Pin to quick picksN4 Pharma Plc Share News (N4P)

Share Price Information for N4 Pharma Plc (N4P)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.625
Bid: 0.60
Ask: 0.65
Change: -0.025 (-3.85%)
Spread: 0.05 (8.333%)
Open: 0.65
High: 0.65
Low: 0.625
Prev. Close: 0.65
N4P Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: Centamin Falls After Gold Production Drops

Mon, 09th Jul 2018 10:08

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - WINNERS----------Just Eat, up 2.4%. RBC Capital raised the online takeaway platform to its Top Pick list.BHP Billiton, up 1.8%. Shares in the Anglo-Australian miner were higher after Reuters reported on Friday that oil major BP is in the lead to acquire the US onshore shale oil and gas assets from BHP after submitting an offer over USD10 billion. BP was down 1.0%.----------FTSE 100 - LOSERS----------Hargreaves Lansdown, down 0.9%. JPMorgan downgraded the funds supermarket to Underweight from Neutral. ----------FTSE 250 - WINNERS----------Stobart Group, up 4.8%. The support services firm said on Saturday that its former chief executive had been re-elected and then immediately dismissed. A majority of shareholders, 51%, voted Andrew Tinkler back onto the board at the company's annual general meeting on Friday, the results of which were delayed until Saturday evening. Tinkler's re-election and his subsequent dismissal were announced within Stobart's Saturday AGM results. In its Saturday statement, Stobart noted that Tinkler's election was passed by the required majority but justified its decision to remove him from the board once again. Tinkler stepped down as chief executive last year but remained on the board. He was removed altogether after accusations of "subverting the company for his own interests" and attempting to cash GBP30 million worth of shares, the Daily Mail said.TalkTalk Telecom Group, up 3.5%. JPMorgan raised the home phone and broadband provider to Neutral from Underweight. ----------FTSE 250 - LOSERS----------Centamin, down 7.5%. The gold miner said second quarter gold production from its Sukari mine in Egypt dropped 25% as underground grades fell below forecast. For the three months to June 30, the miner produced 92,803 ounces of gold compared to 124,641 in the comparative year ago period. In the six months to June 30, production fell 7% to 217,099 ounces form 233,828 ounces year-on-year. In May, the company revised its annual production guidance of between 505,000 and 515,000 ounces at a cash cost of production of USD625 to USD640 per ounce produced and an all-in sustaining cost of USD875 to USD890 per ounce sold. "We have experienced several challenges this year, resulting in the revision of our full year guidance in May," said Chief Executive Officer Andrew Pardey.----------OTHER MAIN MARKET AND AIM - WINNERS----------Legendary Investments, up 17%. The investment company recorded double digit growth in investments and net assets in its recently-ended financial year. In the year to the end of March, the company invested GBP6.2 million versus GBP4.3 million the year before. Net assets saw a 28% increase to GBP6.0 million from GBP4.7 million. During the year, one of Legendary's holdings, Virtualstock Holdings received an investment of GBP4.5 million from European venture capital firm Notion Capital. Legendary holds GBP66 million worth of stake in Virtualstock. In addition, Legendary converted its shares in its Kyrgyz gold asset to shares in Circle Oil Tunisia in December 2017, following Circle Oil Tunisia's acquisition by Dunraven Resources, meaning the the company now holds a 2.0% stake in Dunraven.----------OTHER MAIN MARKET AND AIM - LOSERS----------N4 Pharma, down 52%. The drug reformulation company said that its sildenafil reformulation clinical trial has not met its key target endpoints. The company said that the product formulation will need to be reviewed to assess what changed need to be made to make the reformulated drug viable to N4 Pharma's patent position. "This part of the process of drug reformulation is always going to be a challenge and whilst this preliminary data is clearly disappointing, we will need to see the full set of results expected around the end of August to understand the detailed implications for the formulation," said Chief Executive Officer Nigel Theobald.----------
More News
18 Dec 2023 11:17

N4 Pharma upbeat on recent Nuvec developments

(Sharecast News) - N4 Pharma updated the market on Monday on its ongoing research efforts related to Nuvec, its delivery system designed for cancer treatments and vaccines.

Read more
7 Dec 2023 18:28

TRADING UPDATES: N4 Pharma hails "encouraging" siRNA research

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
7 Dec 2023 13:20

N4 Pharma posts optimistic Nuvec research update

(Sharecast News) - N4 Pharma, a specialist pharmaceutical company focused on developing the Nuvec delivery system for cancer treatments and vaccines, issued an optimistic update on its ongoing in-vitro siRNA research efforts on Thursday.

Read more
1 Dec 2023 14:29

TRADING UPDATES: N4 launches investor hub; Capricorn production falls

(Alliance News) - The following is a round-up of trading updates by London-listed companies, issued on Wednesday, Thursday and Friday and not separately reported by Alliance News:

Read more
28 Sep 2023 13:28

N4 Pharma picks up controlling interest in Nanogenics

(Sharecast News) - Pharmaceutical firm N4 Pharma announced the acquisition of a controlling interest in Nanogenics on Thursday.

Read more
28 Sep 2023 10:20

N4 Pharma shares fall as places shares to fund Nanogenics stake buy

(Alliance News) - N4 Pharma PLC on Thursday said it bought a controlling interest in Nanogenics Ltd, a company with a lipid and peptide-based delivery system called Liptide.

Read more
12 Sep 2023 13:43

N4 Pharma interim loss narrows slightly as business outreach ongoing

(Alliance News) - N4 Pharma PLC on Tuesday said its business outreach is ongoing as it continued to work on getting Nuvec, its delivery system for vaccines and cancer treatment, into clinic.

Read more
25 Jul 2023 12:08

LONDON MARKET MIDDAY: Miners lift FTSE 100 as Fed meeting kicks off

(Alliance News) - Stock prices in London were largely higher at midday on Tuesday, with stimulus talks in China helping lift the mood, as attention turns to the US Federal Reserve which begins its two-day monetary policy meeting later.

Read more
25 Jul 2023 10:12

N4 Pharma shares soar on further patent grant for Nuvec in US

(Alliance News) - N4 Pharma PLC on Tuesday saw its shares rise, as it celebrated a patent grant for Nuvec in the US.

Read more
25 Jul 2023 10:04

AIM WINNERS & LOSERS: N4 Pharma shares jump on grant of US patent

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

Read more
27 Jun 2023 12:13

IN BRIEF: N4 Pharma expands Professor Yu partnership on grant award

N4 Pharma PLC - Derby, England-based pharmaceutical company focused on developing Nuvec, a delivery system for vaccines and cancer treatments - Says it will be supporting the University of Queensland as part of a recent grant award by the Australian Research Council. Professor Chengzhong Yu, senior group leader at the Australian Institute for Bioengineering & Nanotechnology, has been awarded an AUD402,115 grant - around GBP211,366 - to develop an improved nanoparticle delivery system that enhances the performance of messenger ribonucleic acid therapies.

Read more
25 Apr 2023 16:19

TRADING UPDATES: Eckoh expects profit up; LXi REIT refinances facility

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
25 Apr 2023 10:30

AIM WINNERS & LOSERS: FireAngel 2023 earnings below expectations

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

Read more
18 Apr 2023 14:20

TRADING UPDATES: Journeo extends contract; Biome completes fundraise

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
18 Apr 2023 13:13

N4 Pharma reports progress with siRNA work

(Sharecast News) - N4 Pharma updated the market on its ongoing research work on gene-silencing technology siRNA on Tuesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.